217 related articles for article (PubMed ID: 20303627)
41. Hypereosinophilic syndrome: current approach to diagnosis and treatment.
Klion A
Annu Rev Med; 2009; 60():293-306. PubMed ID: 19630574
[TBL] [Abstract][Full Text] [Related]
42. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
43. Oral mucosa lesions in hypereosinophilic syndrome--an update.
Ionescu MA; Murata H; Janin A
Oral Dis; 2008 Mar; 14(2):115-22. PubMed ID: 18194138
[TBL] [Abstract][Full Text] [Related]
44. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
[TBL] [Abstract][Full Text] [Related]
45. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.
Groh M; Rohmer J; Etienne N; Abou Chahla W; Baudet A; Chan Hew Wai A; Chenivesse C; Clisson Rusek I; Cottin V; Decamp M; De Groote P; Delahousse F; Duployez N; Faguer S; Gottrand F; Huang F; Leblanc T; Magnan A; Martin T; Mortuaire G; Néel A; Paris L; Petit A; Rossignol J; Schleinitz N; Soret-Dulphy J; Staumont-Salle D; Terrier B; Terriou L; Viallard JF; Lefèvre G; Kahn JE
Orphanet J Rare Dis; 2023 Apr; 18(1):100. PubMed ID: 37122022
[TBL] [Abstract][Full Text] [Related]
46. The hypereosinophilic syndrome revisited.
Roufosse F; Cogan E; Goldman M
Annu Rev Med; 2003; 54():169-84. PubMed ID: 12525672
[TBL] [Abstract][Full Text] [Related]
47. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
48. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
Lefèvre G; Copin MC; Staumont-Sallé D; Avenel-Audran M; Aubert H; Taieb A; Salles G; Maisonneuve H; Ghomari K; Ackerman F; Legrand F; Baruchel A; Launay D; Terriou L; Leclech C; Khouatra C; Morati-Hafsaoui C; Labalette M; Borie R; Cotton F; Gouellec NL; Morschhauser F; Trauet J; Roche-Lestienne C; Capron M; Hatron PY; Prin L; Kahn JE;
Medicine (Baltimore); 2014 Oct; 93(17):255-266. PubMed ID: 25398061
[TBL] [Abstract][Full Text] [Related]
49. When Blood Cell Counts Matter: Hypereosinophilic Syndrome as a Rare Cause of Ischemic Strokes.
Kaur G; Rodriguez W; Ganev Y; Singh D; Awad A; Orozco L; Overberg R; Edgell RC
Cureus; 2024 May; 16(5):e60557. PubMed ID: 38887335
[TBL] [Abstract][Full Text] [Related]
50. Clinical and Biological Markers in Hypereosinophilic Syndromes.
Khoury P; Makiya M; Klion AD
Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
[TBL] [Abstract][Full Text] [Related]
51. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
52. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC
Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388
[TBL] [Abstract][Full Text] [Related]
53. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
[TBL] [Abstract][Full Text] [Related]
54. A novel acquired cryptic three-way translocation t(2;11;5)(p21.3;q13.5;q23.2) with a submicroscopic deletion at 11p14.3 in an adult with hypereosinophilic syndrome.
Kjeldsen E
Exp Mol Pathol; 2015 Aug; 99(1):50-5. PubMed ID: 25962659
[TBL] [Abstract][Full Text] [Related]
55. [Diagnosis of non-parasitic hypereosinophilia].
Kahn JE; Girszyn N; Blétry O
Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
[TBL] [Abstract][Full Text] [Related]
56. Approach to the therapy of hypereosinophilic syndromes.
Klion AD
Immunol Allergy Clin North Am; 2007 Aug; 27(3):551-60. PubMed ID: 17868864
[TBL] [Abstract][Full Text] [Related]
57. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
58. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
59. Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.
Khoury P; Abiodun AO; Holland-Thomas N; Fay MP; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(1):190-195. PubMed ID: 28757367
[TBL] [Abstract][Full Text] [Related]
60. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
Butterfield JH
Acta Haematol; 2005; 114(1):26-40. PubMed ID: 15995323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
